Abstract | BACKGROUND: PATIENTS: Four hundred patients undergoing macroscopic curative resection for HCC involving the first branch or trunk of the PV between 2001 and 2010 at the 22 institutions were enrolled. We examined the effect of adjuvant hepatic arterial infusion chemotherapy (HAIC) on prognosis and validated the prognostic index consisting of ascites, prothrombin activity, and maximal tumor diameter. RESULTS: Median survival time (MST) and 5-year overall survival rate were 21.5 months and 25.7%. MST of HAIC group was longer than that of non-HAIC group (28.1 months vs. 18.7 months, P = 0.0024). Significant prognostic factors for overall survival were PIVKA-II, tumor diameter, and adjuvant HAIC. MST for patients with prognostic index 0, 1, 2, and 3 was 39.0, 21.1, 18.9, and 5.7 months, respectively (P = 0.005). CONCLUSIONS: Macroscopic curative resection with adjuvant HAIC might provide better survival outcome. Furthermore, the prognostic index was useful to select adequate treatment modalities for patients with HCC with tumor thrombosis in the major PV.
|
Authors | Etsuro Hatano, Shinji Uemoto, Hiroki Yamaue, Masakazu Yamamoto, Japanese Society of Hepato-Biliary-Pancreatic Surgery |
Journal | Journal of hepato-biliary-pancreatic sciences
(J Hepatobiliary Pancreat Sci)
Vol. 25
Issue 9
Pg. 395-402
(Sep 2018)
ISSN: 1868-6982 [Electronic] Japan |
PMID | 30091239
(Publication Type: Journal Article, Multicenter Study)
|
Copyright | © 2018 Japanese Society of Hepato-Biliary-Pancreatic Surgery. |
Chemical References |
|
Topics |
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage)
- Carcinoma, Hepatocellular
(pathology, surgery)
- Cisplatin
(administration & dosage)
- Fluorouracil
(administration & dosage)
- Hepatectomy
- Hepatic Artery
- Humans
- Infusions, Intra-Arterial
- Liver Neoplasms
(pathology, surgery)
- Neoplasm Invasiveness
- Neoplastic Cells, Circulating
(pathology)
- Portal Vein
(pathology, surgery)
- Prognosis
- Retrospective Studies
|